AIROMIR METERED-DOSE AEROSOL

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

SALBUTAMOL (SALBUTAMOL SULFATE)

Saadav alates:

BAUSCH HEALTH, CANADA INC.

ATC kood:

R03AC02

INN (Rahvusvaheline Nimetus):

SALBUTAMOL

Annus:

100MCG

Ravimvorm:

METERED-DOSE AEROSOL

Koostis:

SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG

Manustamisviis:

INHALATION

Ühikuid pakis:

100/200 DOSES

Retsepti tüüp:

Prescription

Terapeutiline ala:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0108887003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2012-01-04

Toote omadused

_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AIROMIR
®
Salbutamol Inhalation Aerosol, Mfr. Std.
100 mcg salbutamol (as Salbutamol Sulfate) per actuation
BRONCHODILATOR
BETA
2
-ADRENERGIC AGONIST
BAUSCH HEALTH, CANADA INC.
2150 St-Elzear Blvd., West
Laval, Quebec H7L 4A8
Canada
DATE OF REVISION:
December 22, 2020
Submission Control No: 241784
_Pr_
_AIROMIR_
_®_
_ Product Monograph Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
......................................................